John Fitzpatrick, M.D.
The TNM Staging System:
A Critical Analysis
|
Peter Clark, M.D., Ph.D.
Preoperative Nutritional
Status and Survival
after Surgery
|
Thomas Powles, M.D.
Detection of Bone Disease
|
Tatjana Traub-Weidinger, M.D.
Is There a Role for PET-CT
in mRCC?
|
Axel Bex, M.D., Ph.D.
Cytoreductive Nephrectomy:
Survival Impact of Surgery
in mRCC
|
Jean Jaques Patard, M.D., Ph.D.
Natural History of Patients
with Local Recurrence after
Nephrectomy for Localized RCC
|
Isaac Witz, M.D.
The Tumor
Microenvironment
in RCC?
|
Sergio Quezada, M.D.
Immune Biology of Cancer
Revisited
|
James Larkin, Ph.D., MRCP
Mechanisms of Resistance
|
Michael Atkins, M.D.
Single Nucleotide Polymorphisms
in RCC: Clinically Relevant
Implications for Daily Practice?
|
Manuela Schmindinger, M.D.
Bone Targeting
|
Vincenzo Ficara, M.D., Ph. D.
Papillary RCC: the SATURN
project
|
Tim O'Brien, M.D.
IVC Thrombus Surgery:
What's New, What's Up,
What's Next
|
Vincenzo Ficarra, Ph.D., M.D.
Strategies for Robotic Surgery
in RCC
|
Steven Joniau, M.D.
Stage 1b RCC: Partial
Nephrectomy the New
Standard-PRO
|
Didier Jacquim, M.D.
Stage 1b RCC: Partial
Nephrectomy the New
Standard-CON
|
Christopher Wood, M.D., FACS
Neoadjuvant Treatment in
Advanced RCC: What is
Next Step?
|
Bradley Leibovich, M.D., FACS
Nomograms and Scores
|
Masatoshi Eto, M.D., Ph.D.
The Role of IFN-alpha
in 2012: Importance of
Targeting the Right Patient
|
Rosalie Fisher, M.D.
Observation is a Valid
Approach in mRCC
|
David McDermott, M.D.
Identification of Potential
IL-2 Responders: the
Ultimate Ambition?
|
Stephane Oudard, M.D., Ph. D.
Vaccines in the Era of TKI:
Much Ado About Nothing?
|
Sergio Bracarda. M.D.
Case: First-line Treatment
in a Multimorbid Patient
|
Alain Ravaud M.D., Ph. D.
Case: First-line Treatment in
a Patient with High Tumor
Burden
|
Fabio Calabro, M.D.
Case: First-line Treatment
Strategy in a Patient with
Low Tumor Burden
|
Joaquim Bellmunt, M.D.
Case: First-line Treatment
in a Patient with Sarcomatoid
RCC
|
Seva Matveev, M.D.
Resection of Multiple
Metastases from RCC
|
Eric Lartigau, Ph.D.
Stereotactic Radiosurgery
for Extracranial Metastases
is a Valid Approach in the
Setting of Metastatic Disease
|
Bertram Haussler, M.D., Ph.D.
Keynote Lecture: Novel Cancer
Agents Will NOT Cause a
Breakdown of Health Care
Systems: Results of the
IGES-Study
|
Manuela Schmidinger, M.D.
Single Nucleotide Polymorphisms
in RCC: Clinically Relevant
Implications for Daily Practice?
|
Luis Aparicio, M.D.
Management of Fatigue
|
Jutta Bergler-Klein, M.D.
Understanding the Mechanisms
of Hypertension and Management
|
Cesary Szczylik, M.D.
Management of Anorexia
|
Brian I. Rini, M.D.
Axitinib IS the New Standard
of Care in 2nd-line: PRO
|
Tim Eisen, M.D.
Axitinib IS the New
Standard of Care in
2nd-line: CON
|
Laure Fournier M.D.
Stage 1b RCC: Partial
Nephrectomy the New
Standard-CON
|
Michael B. Atkins, M.D.
New Targets, New Pathways
|
Sylvie Negrier, M.D.
Combination Strategies:
When and How?
|
Camillo Porta, M.D.
Should Response to 1st-line
Agents Guide the Choice
of Treatment in 2nd-line?
|
|
